- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
- Interventions
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Device · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 1,082
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Transplant; Complications, CMV
- Interventions
- Letermovir 480 mg once daily, Historical/Control
- Drug · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Renal Transplant Recipients
- Interventions
- ENVARSUS®
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- CNI Side Effects
- Interventions
- Cyclosporine & Cellcept, Prograf & Cellcept, Low Dose CNI (Cyclosporine or FK) and Cellcept, Rapamune and Cellcept
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus
- Interventions
- Tacrolimus, Alemtuzumab
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Deceased Donor Kidney Transplant, Acute Kidney Injury, Delayed Graft Function, End Stage Renal Disease, Graft Failure
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 17
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Waltham, Massachusetts + 7 more
- Conditions
- Liver Transplantation
- Interventions
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Baltimore, Maryland + 6 more
- Conditions
- Antibody Mediated Rejection
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Implant or Graft; Rejection
- Interventions
- Belatacept, Tacrolimus, Mycophenolate, rATG, Methylprednisolone, Renal transplant
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Renal Transplant
- Interventions
- Campath-1H
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Kidney Failure, End Stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Palo Alto, California • Atlanta, Georgia
- Conditions
- End-Stage Renal Disease
- Interventions
- Patient Navigation
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Kidney Transplant Recipients, Liver Transplant Recipients
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- BK Virus Infection, BKV Infection, Kidney Transplant
- Interventions
- AIC263029, Placebo
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 10 more
- Conditions
- Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
- Interventions
- Everolimus, Mycophenolic Acid
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Kidney Transplantation
- Interventions
- Thymoglobulin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Gastrointestinal Lesions, Signs and Symptoms, Digestive
- Interventions
- Small bowel capsule endoscopy (SBCE), myfortic
- Procedure · Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Kidney Transplant Recipients, Old Age
- Interventions
- Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Kidney Transplantation
- Interventions
- Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more
- Conditions
- Diabetes Mellitus
- Interventions
- Insulin, Isophane, insulin glargine
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
- Interventions
- Adipose tissue biopsy
- Procedure
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Kidney Transplant Rejection
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Transplant; Failure, Kidney
- Interventions
- Alefacept (ASP0485)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Urinary Tract Infection, Recurrent
- Interventions
- phage therapy, control
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California